Literature DB >> 2835497

Interaction of the bovine papillomavirus type 1 E2 transcriptional control protein with the viral enhancer: purification of the DNA-binding domain and analysis of its contact points with DNA.

C A Moskaluk1, D Bastia.   

Abstract

The E2 gene of bovine papillomavirus type 1 positively and negatively regulates the transcriptional enhancer located in the long control region of the viral genome. The DNA-binding domain of the E2 gene product was suspected to interact with the DNA sequence motif ACCN6GGT. We have shown that the carboxy-terminal 126 amino acids of the E2 protein constitute the DNA-binding domain. In this paper we described the expression of the E2 carboxy terminus in Escherichia coli and its subsequent purification. We provide definitive evidence that the protein recognizes the ACCN6GGT motifs in the viral enhancer. We show by methylation protection, methylation interference, and ethylation interference that the E2 protein contacts the DNA at the GG residues of the consensus sequence on both DNA strands. A gel retardation-DNase I footprint assay has revealed that the E2 DNA-binding domain exhibits different affinities for different ACCN6GGT motifs, indicating that nucleotides other than the conserved ACC and GGT sequences probably modulate the affinity of the DNA sequence for the E2 protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835497      PMCID: PMC253275          DOI: 10.1128/JVI.62.6.1925-1931.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Protein-DNA recognition.

Authors:  C O Pabo; R T Sauer
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

3.  Transformation and replication in mouse cells of a bovine papillomavirus--pML2 plasmid vector that can be rescued in bacteria.

Authors:  N Sarver; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

4.  The N-terminal arms of lambda repressor wrap around the operator DNA.

Authors:  C O Pabo; W Krovatin; A Jeffrey; R T Sauer
Journal:  Nature       Date:  1982-07-29       Impact factor: 49.962

Review 5.  E. coli RNA polymerase interacts homologously with two different promoters.

Authors:  U Siebenlist; R B Simpson; W Gilbert
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

6.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  The primary structure and genetic organization of the bovine papillomavirus type 1 genome.

Authors:  E Y Chen; P M Howley; A D Levinson; P H Seeburg
Journal:  Nature       Date:  1982-10-07       Impact factor: 49.962

8.  Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences.

Authors:  M F Law; D R Lowy; I Dvoretzky; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

9.  The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region.

Authors:  F Thierry; M Yaniv
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

10.  Origin of replication in episomal bovine papilloma virus type 1 DNA isolated from transformed cells.

Authors:  W Waldeck; F Rösl; H Zentgraf
Journal:  EMBO J       Date:  1984-09       Impact factor: 11.598

View more
  29 in total

1.  Conserved cysteine residue in the DNA-binding domain of the bovine papillomavirus type 1 E2 protein confers redox regulation of the DNA-binding activity in vitro.

Authors:  A A McBride; R D Klausner; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Role of glutamic acid 177 of the ricin toxin A chain in enzymatic inactivation of ribosomes.

Authors:  D Schlossman; D Withers; P Welsh; A Alexander; J Robertus; A Frankel
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

3.  Cooperative binding of the E2 protein of bovine papillomavirus to adjacent E2-responsive sequences.

Authors:  P Monini; S R Grossman; B Pepinsky; E J Androphy; L A Laimins
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inactivation of ribosomes.

Authors:  A Frankel; P Welsh; J Richardson; J D Robertus
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

5.  A bovine papillomavirus constitutive enhancer is negatively regulated by the E2 repressor through competitive binding for a cellular factor.

Authors:  S B Vande Pol; P M Howley
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Human papillomavirus type 1 produces redundant as well as polycistronic mRNAs in plantar warts.

Authors:  D A Palermo-Dilts; T R Broker; L T Chow
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Identification of a novel constitutive enhancer element and an associated binding protein: implications for human papillomavirus type 11 enhancer regulation.

Authors:  M T Chin; T R Broker; L T Chow
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

8.  Trans activation by the bovine papillomavirus E2 protein in Saccharomyces cerevisiae.

Authors:  L C Morrissey; J Barsoum; E J Androphy
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Phosphorylation sites of the E2 transcriptional regulatory proteins of bovine papillomavirus type 1.

Authors:  A A McBride; J B Bolen; P M Howley
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

10.  Characterization of the cis elements involved in basal and E2-transactivated expression of the bovine papillomavirus P2443 promoter.

Authors:  B A Spalholz; S B Vande Pol; P M Howley
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.